C57BL/6N-Atm1Brd Csf2tm1(KOMP)Mbp/WtsiOrl

Status

Available to order

EMMA IDEM:11288
International strain nameC57BL/6N-Atm1Brd Csf2tm1(KOMP)Mbp/WtsiOrl
Alternative nameDEPD00527_4_D02
Strain type
Allele/Transgene symbolCsf2tm1(KOMP)Mbp
Gene/Transgene symbolCsf2
DisclaimerPlease note that for EUCOMM and KOMP-CSD mice supplied to the scientific community by INFRAFRONTIER/EMMA:
  1. We can not guarantee a null mutation for Knock-out first alleles (tm1a alleles, see http://www.mousephenotype.org/about-ikmc/targeting-strategies) as the critical exon has not been deleted.
  2. That the structure of the targeted mutation in the ES cells obtained from EUCOMM/KOMP to generate EUCOMM/KOMP mice is not verified by INFRAFRONTIER/EMMA. It is recommended that the recipient confirms the mutation structure.
  3. No check for determining the copy number of the targeting construct in ES cells obtained from EUCOMM/KOMP is done by INFRAFRONTIER/EMMA.
  4. The level of quality control before mice are released is to confirm the individual mouse genotype by short range PCR.

Information from provider

Provider Wellcome Trust Sanger Institute
Provider affiliationWellcome Trust Sanger Institute
Genetic informationThis mouse line originates from KOMP ES clone DEPD00527_4_D02. For further details on the construction of this clone see the page at the IMPC portal.
Phenotypic informationPotential phenotyping data in the IMPC portal
ReferencesNone available

Information from EMMA

Archiving centreInstitut de Transgenose, INTRAGENE, Orléans, France
Animals used for archivingheterozygous C57BL/6N

Disease and phenotype information

MGI phenotypes (gene matching)
  • abnormal abdominal fat pad morphology / MGI
  • abnormal circulating glucose level / MGI
  • lymphoid hyperplasia / MGI
  • abnormal uterus morphology / MGI
  • absent mature ovarian follicles / MGI
  • abnormal lung morphology / MGI
  • increased body weight / MGI
  • decreased body size / MGI
  • abnormal lipid level / MGI
  • increased circulating triglyceride level / MGI
  • increased circulating free fatty acid level / MGI
  • abnormal placenta development / MGI
  • placental labyrinth hypoplasia / MGI
  • postnatal growth retardation / MGI
  • lung inflammation / MGI
  • reduced fertility / MGI
  • abnormal ovulation / MGI
  • decreased litter size / MGI
  • emphysema / MGI
  • abnormal fertility/fecundity / MGI
  • abnormal spleen size / MGI
  • abnormal pulmonary alveolus morphology / MGI
  • increased susceptibility to bacterial infection / MGI
  • abnormal leukocyte physiology / MGI
  • decreased circulating insulin level / MGI
  • abnormal aorta elastic fiber morphology / MGI
  • impaired luteinization / MGI
  • abnormal gluconeogenesis / MGI
  • maternal effect / MGI
  • impaired macrophage chemotaxis / MGI
  • decreased fetal size / MGI
  • fetal growth retardation / MGI
  • decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • decreased ovary weight / MGI
  • decreased energy expenditure / MGI
  • increased susceptibility to parasitic infection / MGI
  • abnormal MHC II cell surface expression on macrophages / MGI
  • decreased circulating progesterone level / MGI
  • abnormal pancreatic islet morphology / MGI
  • behavior/neurological phenotype / MGI
  • hematopoietic system phenotype / MGI
  • increased susceptibility to fungal infection / MGI
  • increased circulating glucose level / MGI
  • increased circulating leptin level / MGI
  • increased fat cell size / MGI
  • abnormal alveolar macrophage morphology / MGI
  • abnormal mesenteric fat pad morphology / MGI
  • prolonged estrous cycle / MGI
  • prolonged diestrus / MGI
  • prolonged metestrus / MGI
  • increased gonadal fat pad weight / MGI
  • increased mesenteric fat pad weight / MGI
  • increased total body fat amount / MGI
  • mortality/aging / MGI
  • increased subcutaneous adipose tissue amount / MGI
  • pulmonary alveolar proteinosis / MGI
  • postnatal lethality, incomplete penetrance / MGI
  • perinatal lethality, incomplete penetrance / MGI
  • prenatal lethality, incomplete penetrance / MGI
  • abnormal aorta collagen fibril morphology / MGI
  • increased food intake / MGI
  • increased spongiotrophoblast size / MGI
  • decreased trophoblast glycogen cell number / MGI
  • increased abdominal adipose tissue amount / MGI

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).